SOUTH SAN FRANCISCO, Calif., Feb. 8 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) announced today the appointment of Daniel S. Janney to the company's board of directors. Mr. Janney previously served on Anesiva's board from November 2000 through December 2005, when he transitioned off the board following the merger of Anesiva and AlgoRx Pharmaceuticals.
"Dan was an excellent contributor to the Anesiva board of directors, and we are very pleased to welcome him back, especially at such an important time in the company's evolution as we prepare to commercialize our first product, Zingo(TM), in the second quarter of 2008," stated John P. McLaughlin, chief executive officer of Anesiva. "We are fortunate to have a strong board of directors at Anesiva with a broad mix of experiences including individuals who are experts in their fields of pain management and biopharma product marketing. Dan serves on the boards of multiple bioscience companies, and we look forward to drawing upon the extensive leadership experience he brings to the table."
Since 1996, Daniel S. Janney has been a managing director of Alta
Partners, a venture capital firm investing in information technologies and
life sciences companies and was a co-founder of the Alta BioPharma effort.
In addition to Anesiva, he currently serves on the board of directors of a
number of companies, including Acureon Pharmaceuticals, Alba Therapeutics,
ChemGenex Pharmaceuticals, Kemia, Phenomix Corporation and ViroBay. He has
been directly involved in the funding and development of over 25 life
sciences companies. Previously, Mr. Janney was a senior investment banker
at Montgomery Securities focusing on life science companies, prior to which
he was at Bankers Trust Company in
|SOURCE Anesiva, Inc.|
Copyright©2008 PR Newswire.
All rights reserved